Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAYMOND THERTULIEN

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1275759581
CMS profile
713931
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$128,805.80

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAYMOND THERTULIEN

NPI 1275759581 · CMS profile ID 713931

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275759581?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAYMOND THERTULIEN, NPI 1275759581, CMS profile ID 713931. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275759581?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAYMOND THERTULIEN, NPI 1275759581, CMS profile ID 713931. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275759581?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAYMOND THERTULIEN, NPI 1275759581, CMS profile ID 713931, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1275759581?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $128,805.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $4,125.0010/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078825236 CMS
GENZYME CORPORATION $108.8010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693956 CMS
GENZYME CORPORATION $8,238.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693958 CMS
GENZYME CORPORATION $255.6110/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693960 CMS
GENZYME CORPORATION $760.9510/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693962 CMS
GENZYME CORPORATION $740.2510/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693964 CMS
GENZYME CORPORATION $8.8310/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693966 CMS
GENZYME CORPORATION $31.1110/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693968 CMS
Janssen Biotech, Inc. $49.5010/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078825024 CMS
PFIZER INC. $122.6910/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130874577 CMS
GENZYME CORPORATION $109.8510/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693940 CMS
Janssen Biotech, Inc. $1,480.8210/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078820491 CMS
Janssen Biotech, Inc. $75.7810/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824073 CMS
Janssen Biotech, Inc. $1,167.6510/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821464 CMS
Janssen Biotech, Inc. $5.5010/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824455 CMS
Janssen Biotech, Inc. $9.2809/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078820577 CMS
Janssen Biotech, Inc. $135.7209/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824935 CMS
GENZYME CORPORATION $659.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693946 CMS
Janssen Biotech, Inc. $4,125.0009/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821115 CMS
Janssen Biotech, Inc. $954.1009/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078822147 CMS
Janssen Biotech, Inc. $113.9509/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824943 CMS
Janssen Biotech, Inc. $3,575.0009/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821767 CMS
Janssen Biotech, Inc. $550.0008/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824765 CMS
Janssen Biotech, Inc. $137.2308/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824144 CMS
Janssen Biotech, Inc. $781.2508/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078822140 CMS
Johnson & Johnson Health Care Systems Inc. $75.4808/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077572960 CMS
Janssen Biotech, Inc. $3,575.0008/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078820537 CMS
Janssen Biotech, Inc. $5.5008/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078823447 CMS
Janssen Biotech, Inc. $910.2408/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824657 CMS
Janssen Biotech, Inc. $120.6508/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821375 CMS
Janssen Biotech, Inc. $4,125.0008/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821504 CMS
Janssen Biotech, Inc. $550.0008/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078821740 CMS
Janssen Biotech, Inc. $1,090.4008/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078820764 CMS
Janssen Biotech, Inc. $129.8307/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078822947 CMS
Janssen Biotech, Inc. $5.5007/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078822282 CMS
Janssen Biotech, Inc. $146.7807/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078825271 CMS
Janssen Biotech, Inc. $5.5006/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078824637 CMS
GENZYME CORPORATION $92.7406/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693928 CMS
GENZYME CORPORATION $126.2106/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693886 CMS
Janssen Scientific Affairs, LLC $1,925.0005/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078853886 CMS
Janssen Biotech, Inc. $5.5004/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078820104 CMS
Janssen Pharmaceuticals, Inc $4,120.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078072802 CMS
Janssen Pharmaceuticals, Inc $1,309.9304/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078072634 CMS
Janssen Pharmaceuticals, Inc $30.3004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078071384 CMS
Janssen Pharmaceuticals, Inc $1,483.3504/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078071982 CMS
Janssen Pharmaceuticals, Inc $75.0104/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078073452 CMS
GENZYME CORPORATION $139.6004/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139693882 CMS
Novartis Pharmaceuticals Corporation $39.7804/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087432140 CMS
AstraZeneca Pharmaceuticals LP $112.7504/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104538874 CMS
Janssen Biotech, Inc. $4,125.0004/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078823691 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84,401.16 258
PY2020 $50,926.44 64
PY2021 $30,116.55 25
PY2022 $94,329.39 118
PY2023 $102,346.24 108
PY2024 $128,805.80 172
PY2025 $69,728.22 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,152.93 13
PY2025 Principal investigator $472,223.13 46
PY2024 Recipient $313.88 1
PY2024 Principal investigator $211,214.58 27
PY2023 Principal investigator $134,757.59 23
PY2022 Principal investigator $10,147.75 6
PY2021 Principal investigator $23,796.97 17
PY2020 Principal investigator $44,144.66 26
PY2019 Principal investigator $57,728.93 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,025.00 12/18/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175432823
Principal investigator 1 SANOFI US SERVICES INC. $8,830.00 12/08/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114326
Principal investigator 1 SANOFI US SERVICES INC. $10,094.00 12/08/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114333
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,173.00 11/26/2025 Non-covered Recipient Entity
Novant Health Clinical Research Llc
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235995133
Principal investigator 1 SANOFI US SERVICES INC. $3,621.00 11/10/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114315
Principal investigator 1 Janssen Research & Development, LLC $8,000.00 11/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175432860
Principal investigator 1 Janssen Research & Development, LLC $2,979.00 10/27/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175432869
Principal investigator 1 Karyopharm Therapeutics Inc. $3,503.00 10/15/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664216
Principal investigator 1 Karyopharm Therapeutics Inc. $3,279.60 10/15/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664220
Principal investigator 1 SANOFI US SERVICES INC. $9,908.00 10/06/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114301
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 10/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma No dispute reported 06/30/2026 1175432834
Principal investigator 1 Janssen Research & Development, LLC $4,072.00 10/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175432901
Principal investigator 1 SANOFI US SERVICES INC. $6,308.00 09/15/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114264
Principal investigator 1 Janssen Research & Development, LLC $4,274.00 09/01/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432854
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/01/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432881
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 08/18/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114249
Principal investigator 1 SANOFI US SERVICES INC. $13,404.00 08/11/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114261
Principal investigator 1 Janssen Research & Development, LLC $4,519.00 07/31/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432895
Principal investigator 1 SANOFI US SERVICES INC. $9,688.00 07/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114227
Principal investigator 1 SANOFI US SERVICES INC. $3,887.00 07/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114235
Principal investigator 1 SANOFI US SERVICES INC. $14,816.00 07/21/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114245
Principal investigator 1 Karyopharm Therapeutics Inc. $350.00 07/09/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664222
Principal investigator 1 SANOFI US SERVICES INC. $8,934.00 07/07/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114223
Principal investigator 1 Janssen Research & Development, LLC $2,998.00 06/30/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432918
Principal investigator 1 Janssen Research & Development, LLC $907.00 06/30/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432945
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 06/23/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114213
Principal investigator 1 SANOFI US SERVICES INC. $15,313.00 06/23/2025 Covered Recipient Teaching Hospital
Presbyterian Hospital Huntersville
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226114219
Principal investigator 1 Karyopharm Therapeutics Inc. $50,825.00 06/16/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664212
Principal investigator 1 Karyopharm Therapeutics Inc. $19,088.30 06/16/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664214
Principal investigator 1 Janssen Research & Development, LLC $5,096.00 05/26/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432911
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 05/09/2025 Non-covered Recipient Entity
Novant Health Clinical Research LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664218
Principal investigator 1 SANOFI US SERVICES INC. $8,830.00 05/05/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086884
Principal investigator 1 Janssen Research & Development, LLC $5,684.00 05/02/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432829
Principal investigator 1 Janssen Research & Development, LLC $10,804.00 04/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432937
Principal investigator 1 SANOFI US SERVICES INC. $5,200.00 04/02/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086876
Principal investigator 1 SANOFI US SERVICES INC. $6,311.00 04/02/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086880
Principal investigator 1 Celgene Corporation $1,910.00 03/19/2025 Non-covered Recipient Entity
Advarra
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222307027
Principal investigator 1 SANOFI US SERVICES INC. $12,453.00 03/17/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086871
Recipient GlaxoSmithKline, LLC. $10.92 03/12/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144841
Recipient GlaxoSmithKline, LLC. $88.46 03/12/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147066
Recipient GlaxoSmithKline, LLC. $68.65 03/12/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147069
Recipient GlaxoSmithKline, LLC. $43.00 03/12/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147074
Principal investigator 1 Janssen Research & Development, LLC $4,193.00 03/03/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432941
Recipient GlaxoSmithKline, LLC. $31.02 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144827
Recipient GlaxoSmithKline, LLC. $240.96 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144832
Recipient GlaxoSmithKline, LLC. $80.76 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144837
Recipient GlaxoSmithKline, LLC. $37.18 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144845
Recipient GlaxoSmithKline, LLC. $17.86 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144850
Recipient GlaxoSmithKline, LLC. $45.59 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192144854
Recipient GlaxoSmithKline, LLC. $87.33 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147057
Recipient GlaxoSmithKline, LLC. $115.08 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147061
Recipient GlaxoSmithKline, LLC. $286.12 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192147078
Principal investigator 1 SANOFI US SERVICES INC. $9,038.00 02/18/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086864
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,826.92 01/27/2025 Non-covered Recipient Entity
Novant Health Cancer Institute Forsyth
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235995135
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,434.31 01/27/2025 Non-covered Recipient Entity
Novant Health Cancer Institute
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235995137
Principal investigator 1 SANOFI US SERVICES INC. $8,935.00 01/27/2025 Non-covered Recipient Entity
Presbyterian Hospital, Dba Novant Health Presbyt
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226086868
Principal investigator 1 Janssen Research & Development, LLC $3,723.00 01/24/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432874
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 01/17/2025 Non-covered Recipient Entity
NOVANT HEALTH CLINICAL RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175432840
Principal investigator 1 Celgene Corporation $122,789.00 01/08/2025 Non-covered Recipient Entity
Novant Health Clinical Research Llc
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222306419